罗妥木单抗

罗妥木单抗（INN：Robatumumab；开发代号：SCH 717454和MK-7454）是默克和先灵葆雅生产的单克隆抗体和抗肿瘤药物。它与CD221（或称胰岛素样生长因子1受体）结合。^[1]

针对结直肠癌、骨肉瘤和尤文氏肉瘤患者的II期临床试验已经完成。^[2]^[3]此后默克公司停止了该药物的开发。^[4]

参考资料

^ "robatumumab", p. 337 in: Quality Assurance and Safety of Medicines. Encrenaz C , 编. Proposed International Nonproprietary Names: List 100 (PDF). WHO Drug Information. 2008, 22 (4): 311–67 [2024-01-24]. （原始内容存档 (PDF)于2022-01-20）.
^ Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, et al. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatric Blood & Cancer. October 2016, 63 (10): 1761–70. PMC 5129487 . PMID 27362300. doi:10.1002/pbc.26087.
^ Clinical trial number NCT00551213 for "A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)" at ClinicalTrials.gov
^ Robatumumab. Adis Insight. Springer Nature Switzerland AG. [2024-01-24]. （原始内容存档于2024-01-24）.